Major pharmaceutical companies, including AstraZeneca, Pfizer, and Gilead, have made public their findings on new cancer treatments.
The American Society of Clinical Oncology (ASCO) annual meeting was held in Chicago, featuring over 5,000 research abstracts on various cancer treatments and studies. Several pharmaceutical giants and biotech companies presented promising data, including AstraZeneca, Pfizer, Gilead, and Merck. Here are the key highlights:
* AstraZeneca’s Enhertu, in combination with pertuzumab, showed impressive results in treating HER2-positive metastatic breast cancer, with patients living 41 months without disease progression, compared to 27 months with standard treatment.
* Pfizer’s Braftovi, combined with two other cancer treatments, doubled survival time for patients with aggressive colorectal cancer, cutting deaths by 51% and reducing disease progression by 47%.
* Gilead and Merck’s combination of Trodelvy and Keytruda lowered the risk of aggressive breast cancer worsening by 35% when used as an initial treatment.
* Merck and Daiichi Sankyo’s experimental treatment, patritumab deruxtecan, disappointed in a lung cancer trial, failing to prolong patient lives, but the companies plan to advance the treatment for breast cancer.
* Amgen’s Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients.
In other healthcare news, Bristol Myers Squibb partnered with BioNTech to develop a next-generation cancer immunotherapy, which could rival existing treatments like Keytruda. The FDA also approved the first-ever AI platform for breast cancer prediction from Boston-based Clairity, which could help reduce over-screening and improve early detection.
Additionally, Amazon Pharmacy announced new features for caregivers and Medicare Part D patients, allowing customers to directly access PillPack’s services and manage medications on behalf of their loved ones. The company’s online pharmacy is part of its effort to push into the healthcare industry, following its acquisition of primary care provider One Medical in 2022.
Overall, the ASCO meeting highlighted significant advancements in cancer treatment, with several promising therapies and studies showing improved patient outcomes. The healthcare industry continues to evolve, with companies investing in innovative technologies and partnerships to improve patient care and access to treatments.
Nomura elevates price target for Fortis Healthcare, retains ‘buy’ rating, reports Medical Buyer
Nomura, a research firm, has revised its price target for Fortis Healthcare from Rs 700 to Rs 820, while maintaining its “buy” rating. The firm attributes this increase to the company’s strong growth prospects, driven by its existing infrastructure and strategic expansions. According to Nomura, the Indian hospital sector has seen significant re-rating over the past five years, resulting in rich valuations. However, Fortis Healthcare is expected to trade in line with or at a premium to its peers due to its robust growth prospects.
The hospital segment of Fortis Healthcare has shown impressive growth, with revenue increasing by 14.8% in fiscal 2025, driven by higher occupancy and a 9% increase in average revenue per occupied bed. Nomura expects the hospital segment’s EBITDA margin to expand to mid-to-high 20s in the medium term. The firm also notes that while the diagnostics segment has underperformed due to a change in brand name, it expects a gradual improvement in growth and EBITDA margin over time.
Nomura is bullish on Fortis Healthcare’s outlook, citing its extensive network of hospitals and collection centers across the country. The firm believes that the company can effectively leverage its network to improve its financial performance over time. With its strong growth prospects and existing infrastructure, Fortis Healthcare is well-positioned to close the gap with its peers and achieve higher valuations. Overall, Nomura’s revised price target and “buy” rating indicate a positive outlook for the company’s future performance.
The brokerage firm’s analysis highlights the potential for Fortis Healthcare to improve its financial performance, driven by its hospital segment’s growth and the expected recovery of its diagnostics segment. With its large and geographically widespread network, the company is well-positioned to capitalize on the growing demand for healthcare services in India. As a result, investors may consider Fortis Healthcare as a promising investment opportunity, driven by its strong growth prospects and improving financial performance.
Glenmark Pharmaceuticals’ (NSE:GLENMARK) financial results appear less impressive upon closer examination.
Glenmark Pharmaceuticals’ latest earnings report may appear impressive at first glance, but a closer examination reveals some underlying weaknesses. The company’s net profit increased by 15.6% year-over-year, reaching ₹2.16 billion, and revenue grew by 7.2% to ₹27.45 billion. However, these numbers are not as strong as they seem.
One major concern is the decline in the company’s operating margins, which fell to 13.4% from 15.4% in the same quarter last year. This decrease is largely due to higher research and development expenses, which rose by 34.4% year-over-year. While investing in R&D is essential for pharmaceutical companies, the significant increase in expenses has put pressure on Glenmark’s profitability.
Another issue is the company’s dependence on a few key products, which account for a significant portion of its revenue. The sales of these products have been declining, and Glenmark has not been able to offset this decrease with new launches or growth in other areas. This dependence on a limited number of products makes the company vulnerable to market fluctuations and competition.
Furthermore, Glenmark’s debt has increased, with a debt-to-equity ratio of 0.45, up from 0.34 in the previous year. The company’s interest expenses have also risen, which has further eroded its profitability. Glenmark’s return on equity (ROE) has declined to 12.1% from 14.1% in the same quarter last year, indicating a decrease in the company’s ability to generate profits from its shareholders’ capital.
In addition, Glenmark’s guidance for the full year is cautious, with the company expecting revenue growth of 8-10% and operating margin expansion of 50-100 basis points. This guidance is lower than analyst expectations, which could lead to a negative reaction from investors.
Overall, while Glenmark Pharmaceuticals’ latest earnings report may appear strong at first glance, a closer examination reveals several underlying weaknesses. The company’s declining operating margins, dependence on a few key products, increasing debt, and declining ROE are all causes for concern. Glenmark needs to address these issues to achieve sustainable growth and improve its profitability in the long term. Investors should exercise caution and carefully evaluate the company’s prospects before making any investment decisions.
Sun Pharmaceutical Industries plans to allocate $100 million for the commercialisation of its specialty products during the current fiscal year.
Sun Pharmaceutical Industries, a leading drug manufacturer, has announced plans to invest $100 million in the current fiscal year to commercialize innovative products, with a focus on strengthening its specialty business. The investment will be used to launch two new products, Unloxcyt and Leqselvi, which are indicated for the treatment of metastatic cutaneous squamous cell carcinoma and severe alopecia areata, respectively.
The company’s specialty sales have shown significant growth, with a 17.1% increase to $1,216 million in FY25, and an 8.6% increase to $295 million in the January-March quarter. Chairman and Managing Director Dilip Shanghvi stated that the company is seeking a partner for the future development and commercialization of MM-II, a product for osteoarthritis pain, and is planning a trial of GL0034 in type 2 diabetes.
Sun Pharma has also agreed to acquire Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology, and is awaiting approval from the USFDA. The acquisition is expected to accelerate patient access to Unloxcyt, which has recently received approval from the USFDA.
The company has reported a total sales of ₹5,20,41 crore in FY25 and expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. The FY26 R&D spend is expected to be 6-8% of sales. Shanghvi stated that the company believes in the potential of its products and is committed to investing in their development and commercialization.
Overall, Sun Pharma’s focus on specialty products and innovative therapies is expected to drive growth and expansion in the coming fiscal year. The company’s investment in new products and acquisitions is expected to strengthen its position in the market and provide access to new treatments for patients. With a strong pipeline of products and a commitment to R&D, Sun Pharma is well-positioned for future growth and success.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.